Literature DB >> 22098947

Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease.

Maria Franzini1, Irene Fornaciari, Vanna Fierabracci, Hassan Aziz Elawadi, Valeria Bolognesi, Simona Maltinti, Angelo Ricchiuti, Nicola De Bortoli, Santino Marchi, Alfonso Pompella, Claudio Passino, Michele Emdin, Aldo Paolicchi.   

Abstract

BACKGROUND: Serum gamma-glutamyltransferase (GGT) activity is a sensitive but non-specific marker of non-alcoholic fatty liver disease (NAFLD). Recently, four GGT fractions (big-, medium-, small-, free-GGT) were described in humans. AIM: We aimed to investigate whether a specific GGT fraction pattern is associated with NAFLD.
METHODS: Gamma-glutamyltransferase fractions were determined in patients with NAFLD (n = 90), and compared with those in control subjects (n = 70), and chronic hepatitis C (CHC, n = 45) age and gender matched.
RESULTS: Total GGT was elevated in NAFLD as compared to controls (median, 25°-75° percentile: 39.4, 20.0-82.0 U/L vs. 18.4, 13.2-24.9 U/L respectively, P < 0.001). All fractions were higher in NAFLD than in controls (P < 0.001). The b-GGT showed the highest diagnostic accuracy for NAFLD diagnosis [area under ROC curve (ROC-AUC): 0.85; cut-off 2.6 U/L, sensitivity 74%, specificity 81%]. Also subjects with CHC showed increased GGT (41.5, 21.9-84.5 U/L, P < 0.001 vs. controls, P = n.s. vs. NAFLD), as well as m-, s-, and f-GGT, while b-GGT did not show any significant increase (P = n.s. vs. HS, P < 0.001 vs. NAFLD). In subjects with CHC, s-GGT showed the best diagnostic value (ROC-AUC: 0.853; cut-off 14.1 U/L, sensitivity 73%, specificity 90%). Serum GGT did not show any value in the differential diagnosis between NAFLD and CHC (ROC-AUC 0.507, P = n.s.), while b-GGT/s-GGT ratio showed the highest diagnostic accuracy for distinguishing NAFLD and CHC (ROC-AUC: 0.93; cut-off value 0.16, sensitivity 82%, specificity 90%).
CONCLUSIONS: b-GGT increases in NAFLD, but not in CHC. GGT fraction analysis might help in improving the sensitivity and specificity of the diagnosis of NAFLD and other liver dysfunctions.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098947     DOI: 10.1111/j.1478-3231.2011.02673.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  26 in total

Review 1.  Gamma-glutamyl transferase and cardiovascular disease.

Authors:  Gjin Ndrepepa; Adnan Kastrati
Journal:  Ann Transl Med       Date:  2016-12

Review 2.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

3.  γ-Glutamyltransferase Fractions in Obese Subjects with Type 2 Diabetes: Relation to Insulin Sensitivity and Effects of Bariatric Surgery.

Authors:  Maria Franzini; Veronica Musetti; Daniela Guarino; Laura Caponi; Aldo Paolicchi; Michele Emdin; Ele Ferrannini; Monica Nannipieri
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

4.  The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Christopher P Cannon; Michael Blazing; Jeong-Gun Park; Michelle L O'Donoghue; Raymond T Chung; Robert P Giugliano
Journal:  Int J Cardiol       Date:  2018-05-26       Impact factor: 4.164

5.  Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study.

Authors:  Maria Franzini; Irene Fornaciari; Jian Rong; Martin G Larson; Claudio Passino; Michele Emdin; Aldo Paolicchi; Ramachandran S Vasan
Journal:  Clin Chim Acta       Date:  2012-12-14       Impact factor: 3.786

6.  Relationship of serum gamma-glutamyltransferase levels with pulmonary function and chronic obstructive pulmonary disease.

Authors:  Hyun-Woo Kim; Seock-Hwan Lee; Duk-Hee Lee
Journal:  Lung       Date:  2014-07-11       Impact factor: 2.584

7.  The Serum Gamma Glutamyl Transpeptidase - A Non invasive Diagnostic Bio Marker of Chronic Anicteric Non Alcoholic Liver Diseases.

Authors:  Krishnamurthy H A
Journal:  J Clin Diagn Res       Date:  2013-03-09

Review 8.  Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.

Authors:  Kuang-Chun Hu; Horng-Yuan Wang; Sung-Chen Liu; Chuan-Chuan Liu; Chung-Lieh Hung; Ming-Jong Bair; Chun-Jen Liu; Ming-Shiang Wu; Shou-Chuan Shih
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  Associations between total serum GGT activity and metabolic risk: MESA.

Authors:  Ryan Bradley; Annette L Fitzpatrick; Nancy S Jenny; Duk-Hee Lee; David R Jacobs
Journal:  Biomark Med       Date:  2013-10       Impact factor: 2.851

10.  Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China.

Authors:  Liwei Ji; Xintian Cai; Yang Bai; Tao Li
Journal:  Int J Gen Med       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.